BIRMINGHAM, Ala.--(BUSINESS WIRE)-- #T1D--TIXiMED, Inc. (www.TIXiMED.com), a clinical-stage pharmaceutical company developing a novel disease-modifying oral therapy for type 1 diabetes (T1D), today announced the initiation of the Phase 1b Multiple Ascending Dose (MAD) study of TIX100 (NCT07675590), an investigational oral inhibitor of thioredoxin-interacting protein (TXNIP). The TIX100 MAD study is a double-blind, randomized, placebo-controlled trial evaluating the safety, tolerability, and phar